uniQure (NASDAQ:QURE) Insider Sells $67,197.24 in Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 1,434 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $46.86, for a total transaction of $67,197.24. Following the completion of the sale, the insider directly owned 168,235 shares in the company, valued at approximately $7,883,492.10. This trade represents a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Walid Abi-Saab also recently made the following trade(s):

• On Tuesday, June 30th, Walid Abi-Saab sold 30,000 shares of uniQure stock. The shares were sold at an average price of $46.42, for a total transaction of $1,392,600.00.
• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00.

uniQure Stock Performance

Shares of QURE stock opened at $41.81 on Friday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $30.05 and a 200 day moving average price of $23.73. The company has a market cap of $2.64 billion, a P/E ratio of -12.01 and a beta of 0.90. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Sell-side analysts predict that uniQure N.V. will post -3.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Chardan Capital boosted their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. The Goldman Sachs Group raised their price objective on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 18th. Royal Bank Of Canada boosted their price objective on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Mizuho upped their target price on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Finally, Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $64.17.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $80 price target while raising multiple earnings estimates for uniQure, including near- and longer-term forecasts. The improved outlook suggests analysts see stronger future profitability than before. uniQure analyst update
• Positive Sentiment: Recent technical coverage highlighted that QURE is trading above a golden cross, which traders often view as a bullish momentum signal and a possible support level. Zacks golden cross article
• Neutral Sentiment: Media attention also included a comparison piece on uniQure versus Viridian Therapeutics and a short-squeeze watchlist mention, which may be adding trading interest but does not directly change fundamentals. AAII comparison article
• Negative Sentiment: Director Jack Kaye and insider Walid Abi-Saab both sold shares in recent SEC filings. Although the trades were made under pre-arranged 10b5-1 plans, insider selling can still weigh on sentiment. Jack Kaye SEC filing Walid Abi-Saab SEC filing

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC purchased a new stake in uniQure in the fourth quarter valued at approximately $28,000. IFP Advisors Inc purchased a new position in shares of uniQure during the fourth quarter worth approximately $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure in the 4th quarter valued at $48,000. CIBC Private Wealth Group LLC purchased a new stake in uniQure in the 3rd quarter valued at $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in uniQure by 42.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 906 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.